Microbial Influences of Mucosal Immunity in Rheumatoid Arthritis

Wilson, Timothy M.; Trent, Brandon; Kuhn, Kristine A.; Demoruelle, M. Kristen

doi:10.1007/s11926-020-00960-1

Cited by 12 publications

(6 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Факторы внешней среды (инфекции, курение, загрязнение воздуха), дисбиоз слизистой дыхательных путей [46], гастроэзофагеальная рефлюксная болезнь, иммунные нарушения, связанные со старением организма (immunosenescence) вносят вклад в развитие как самого РА, так и поражения легких [16]. У пациентов с РА носительство HLA-DRB1 SE (shared epitope) ассоциируется с гиперцитруллинированием белков, индуцированным курением [14,47].…”

Section: индивидуальныеunclassified

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Насонов

Ananieva²,

Avdeev

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an immune-mediated rheumatic disease (IMRDs) characterized by chronic erosive arthritis and systemic damage to internal organs, leading to early disability and reduced life expectancy in patients. A particularly important place among the systemic manifestations of RA is occupied by interstitial lung diseases (ILD) – the most severe form of pulmonary pathology in RA, defined as RA-ILD, which is pathogenetically associated with risk factors (smoking, etc.) and autoimmune mechanisms underlying RA. RA-ILD is a subtype of RA characterized by a severe course and a poor prognosis и неблагоприятным прогнозом. The review presents new data regarding risk factors and biomarkers for RA-ILD; modern diagnostic capabilities based on the use of functional lung tests, high-resolution computed tomography, ultrasound examination of the lungs. Particular attention is paid to the efficacy and safety of pharmacotherapy, including methotrexate, biologics, JAK inhibitors, and antifibrotic therapy. An algorithm for the pharmacotherapy of RA-ILD has been proposed.

show abstract

Section: индивидуальныеunclassified

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Насонов

Ananieva²,

Avdeev

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

“…Regarding the effect on the expression of TLRs of APCs, this may contribute to an imbalance in the Th17/Treg cell ratio and this local immune response could lead to systemic autoimmunity (Horta-Baas et al, 2017). Thus, the existing literature suggests that GM could contribute to or prevent the expansion of autoimmunity and inflammation during the preclinical and clinical phases of RA, and GM could influence transitions between these phases (Wilson et al, 2020). Figure 1 summarizes the pathophysiology of RA and the proposed mechanisms whereby GM could participate in triggering autoimmunity and systemic inflammation in susceptible individuals.…”

Section: Gut Microbiota Immune System and Rheumatoid Arthritismentioning

confidence: 99%

Probiotic Supplementation for Rheumatoid Arthritis: A Promising Adjuvant Therapy in the Gut Microbiome Era

et al. 2021

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease that ultimately leads to joint destruction and functional disability. Although the exact etiology of RA is not fully understood, it is well established that gut microbiota (GM) plays a vital role in the pathogenesis of RA, with accumulating evidence suggesting that gut dysbiosis induces a chronic inflammatory response that may be linked to disease development. Of interest, patients with RA have significant changes in the intestinal microbiota compared to healthy controls, and several studies have suggested the use of probiotics as a possible adjuvant therapy for RA. Benefits of probiotic supplementation were reported in animal models of arthritis and human studies, but the current evidence regarding the effect of probiotic supplementation in the management of RA remains insufficient to make definite recommendations. Several different strains of Lactobacillus and Bifidobacteria, as single species or in mixed culture, have been investigated, and some have demonstrated beneficial effects on disease activity in RA human subjects. As of now, L.casei probiotic bacteria seems to be the strongest candidate for application as adjuvant therapy for RA patients. In this review, we highlight the role of GM in the development and progression of RA and summarize the current knowledge on the use of probiotics as a potential adjuvant therapy for RA. We also review the proposed mechanisms whereby probiotics regulate inflammation. Finally, the role of fermented foods is discussed as a possible alternative to probiotic supplements since they have also been reported to have health benefits.

show abstract

“…Accumulating evidence from epidemiological and translational studies indicates that alterations in the composition of the microbial flora at mucosal sites may contribute to the development and perpetuation of many immune-mediated inflammatory diseases [47]. The presence of dysbiosis has been demonstrated in the oral cavity, lungs, and gut of patients with RA, and is thought to have effects on inflammation and activation of autoreactive T and B cells at multiple time-points [48]. Of particular relevance to disease pathogenesis, specific bacteria have been associated with citrullinated protein production [49], and perturbations of the mucosal microbiome are already seen in ACPA-positive individuals at risk of developing RA [50,51].…”

Section: Microbial Dysbiosis and Mucosal Inflammationmentioning

confidence: 99%

The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis

Stefano

D’Onofrio

Manzo

et al. 2021

IJMS

View full text Add to dashboard Cite

Differences in clinical presentation, response to treatment, and long-term outcomes between autoantibody-positive and -negative rheumatoid arthritis (RA) highlight the need for a better comprehension of the immunopathogenic events underlying the two disease subtypes. Whilst the drivers and perpetuators of autoimmunity in autoantibody-positive RA have started to be disclosed, autoantibody-negative RA remains puzzling, also due its wide phenotypic heterogeneity and its possible misdiagnosis. Genetic susceptibility appears to mostly rely on class I HLA genes and a number of yet unidentified non-HLA loci. On the background of such variable genetic predisposition, multiple exogeneous, endogenous, and stochastic factors, some of which are not shared with autoantibody-positive RA, contribute to the onset of the inflammatory cascade. In a proportion of the patients, the immunopathology of synovitis, at least in the initial stages, appears largely myeloid driven, with abundant production of proinflammatory cytokines and only minor involvement of cells of the adaptive immune system. Better understanding of the complexity of autoantibody-negative RA is still needed in order to open new avenues for targeted intervention and improve clinical outcomes.

show abstract

Microbial Influences of Mucosal Immunity in Rheumatoid Arthritis

Cited by 12 publications

References 84 publications

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Probiotic Supplementation for Rheumatoid Arthritis: A Promising Adjuvant Therapy in the Gut Microbiome Era

The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis

Contact Info

Product

Resources

About